Skip to Content
Merck
CN
  • IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.

Nature immunology (2002-12-17)
Sergei V Kotenko, Grant Gallagher, Vitaliy V Baurin, Anita Lewis-Antes, Meiling Shen, Nital K Shah, Jerome A Langer, Faruk Sheikh, Harold Dickensheets, Raymond P Donnelly
ABSTRACT

We report here the identification of a ligand-receptor system that, upon engagement, leads to the establishment of an antiviral state. Three closely positioned genes on human chromosome 19 encode distinct but paralogous proteins, which we designate interferon-lambda1 (IFN-lambda1), IFN-lambda2 and IFN-lambda3 (tentatively designated as IL-29, IL-28A and IL-28B, respectively, by HUGO). The expression of IFN-lambda mRNAs was inducible by viral infection in several cell lines. We identified a distinct receptor complex that is utilized by all three IFN-lambda proteins for signaling and is composed of two subunits, a receptor designated CRF2-12 (also designated as IFN-lambdaR1) and a second subunit, CRF2-4 (also known as IL-10R2). Both receptor chains are constitutively expressed on a wide variety of human cell lines and tissues and signal through the Jak-STAT (Janus kinases-signal transducers and activators of transcription) pathway. This receptor-ligand system may contribute to antiviral or other defenses by a mechanism similar to, but independent of, type I IFNs.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Interferon-λ human, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Sigma-Aldrich
IFN-lambda 2 from mouse, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture